Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

All News

Product Approvals and Launches

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Compendia

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

Partners

Polls and Quizzes

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

BIOSIMILAR APPROVALS

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

Articles

Explore groundbreaking developments in biosimilars, including patent lawsuits, new ustekinumab launches, and innovative access strategies for patients.

Litigation, Launch, and Lower Costs: 3 Big Moves in the US Biosimilar Space

Cameron Santoro is an associate editor for The Center for Biosimilars

Videos

Here are the top 5 biosimilar articles for the week of August 11, 2025.

The Top 5 Biosimilar Articles for the Week of August 11

Biosimilar LY01011 is equivalent to the reference product denosumab for treating bone metastases in solid tumors, demonstrating similar efficacy in reducing bone metabolism biomarkers, comparable safety profiles, and a lack of unexpected adverse reactions.

Denosumab Biosimilar LY01011 Shows Equivalence to Reference Product for Bone Metastases

Discover the latest advancements in biosimilars, including tocilizumab's new indication, and partnerships for omalizumab and ranibizumab.

Biosimilar Business Recap: Updates on Tocilizumab, Omalizumab, and Ranibizumab Products

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

About

Editorial

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

The Center for Biosimilars - Biosimilars, Health Economics & Insights

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

View

Each is an abbreviation of the biosimilar brand name.

Suffixes are deliberately random and nonsensical.

They signify key differences between biosimilars and originator brands.

Physicians prefer using suffixes rather than brand names.

For background reading on this topic, click 

Check out the results from our last poll:

Biosimilar suffixes were intended to help with pharmacovigilance, but they are not widely understood. 

Business & Practice

Poll: How Much Do You Know About Biosimilar Suffixes?

Poll: How Much Do You Know About Biosimilar Suffixes?

Newsletter